ProMIS Neurosciences presents data from PMN310 Phase1a trial

ProMIS Neurosciences (PMN) presented positive results from all five cohorts from the Phase 1a, single ascending dose clinical trial of its lead product candidate, PMN310, at the 17th Clinical Trials on Alzheimer’s Disease, CTAD, Conference taking place from October 29 – November 1, 2024 in Madrid, Spain. PMN310 was generally well-tolerated in all five single-ascending dose cohorts of the Phase 1a clinical trial and, importantly, crossed the blood brain barrier in healthy volunteers in a dose dependent manner with pharmacokinetics suggesting that monthly dosing may provide levels of PMN310 adequate for target engagement in AD patients.